Stockreport

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy [Yahoo! Finance]

Alterity Therapeutics Limited - American Depositary Shares  (ATHE) 
PDF – Objective Biomarkers Demonstrated Improvement Consistent with Clinical Findings – – ATH434 was Well-Tolerated with No Safety Signals Detected – MELBOURNE, Austral [Read more]